AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca emerging Markets — Total revenue ($M) ($M)
Form 6-K Quarterly & Form 20-F Regional Revenue Table
Latest, FY2025
15,303
Period ended Dec 31, 2025
Change on a year earlier
+11.9%
13,675 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emerging Markets — Total revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15,303 | +11.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 13,675 | +13.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 12,025 | +2.4% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 11,745 | -4.4% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 12,281 | +41.0% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 8,711 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up emerging markets — total revenue ($m)
- Emerging Markets — Share of total revenue (%)26.0% · FY2025
- Emerging Markets — Revenue YoY actual (%)12.0% · FY2025
- Emerging Markets — Revenue YoY at constant exchange rates / CER (%)14.0% · FY2025
- China — Total revenue ($M)6,654 · FY2025
- Emerging Markets excluding China — Total revenue ($M)8,649 · FY2025
Cite this data
StockData. (2026). AstraZeneca Emerging Markets — Total revenue ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/rev_reg_em_total
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.